Nitinotes Achieves CE Mark Approval for EndoZip System
Approval enables European launch of a faster, simpler, cost-effective ESG procedure.
Recent advancements in medical technology have opened doors for innovative solutions in obesity treatment. Nitinotes Ltd., a leading medical device company, has made headway by receiving the CE Mark approval for its groundbreaking EndoZip System. This is the first fully automated suturing platform designed specifically for endoscopic sleeve gastroplasty (ESG), marking a significant milestone for the company.
The CE Mark allows Nitinotes to begin its commercialization efforts throughout the European Union and other markets that recognize CE certification. This approval comes at a critical time as obesity continues to pose a global health challenge, with over 650 million adults affected worldwide.
Despite the high prevalence of obesity, there remains a substantial gap between traditional medical treatments, like GLP-1 therapies, and more invasive options such as bariatric surgery. ESG is gaining traction as a minimally invasive solution for patients with a Body Mass Index (BMI) ranging from 30 to 40 kg/m², particularly those who have struggled with conventional approaches like diet and exercise.
One of the key features of the EndoZip System is its automation of the suturing process, which transforms ESG into a more efficient procedure. Unlike traditional methods that require two clinicians and are time-consuming, EndoZip allows a single physician to perform a fast outpatient procedure with a streamlined learning curve. This shift not only enhances efficiency but also makes it more accessible for bariatric surgeons, ultimately setting a new standard in treatment options.
Nitinotes' CEO, Lloyd Diamond, emphasizes the significance of this achievement: "CE Mark approval of EndoZip is a pivotal milestone for Nitinotes. This achievement validates the safety and performance of our technology and paves the way for commercialization in Europe. With EndoZip, we have the potential to dramatically expand patient access to a safe, durable, minimally invasive obesity treatment while creating significant value for providers and healthcare systems."
The company is poised to launch EndoZip in select European centers of excellence, fostering clinical adoption and gathering real-world data to support penetration into the broader market. Alongside these efforts, Nitinotes is preparing for an essential U.S. Investigational Device Exemption (IDE) trial, which will facilitate their submission to the FDA and support entry into the largest market for obesity treatment.
About Nitinotes
Nitinotes is a private medical device company at the forefront of innovation in obesity treatment. Their flagship product, EndoZip™, is designed to offer a consistent, reproducible, and minimally invasive approach to esophageal surgery, providing an alternative for Class I and II obesity patients.
For more information about the EndoZip System and Nitinotes, visit their official website.
Media Contact:
Offer Nonhoff
Chief Financial Officer
Frequently Asked Questions
What is the EndoZip System?
The EndoZip System is the first fully automated suturing platform designed for endoscopic sleeve gastroplasty, aimed at treating obesity.
What does CE Mark approval signify?
CE Mark approval indicates that a product meets European safety and performance requirements, allowing it to be marketed in the EU.
How does the EndoZip System improve ESG procedures?
By automating suturing, it simplifies the ESG procedure, allowing it to be performed by a single physician and reducing procedure time.
Why is addressing obesity important?
Obesity is a global health crisis, linked to various health issues, and effective treatment options like ESG are vital in helping affected individuals achieve better health outcomes.
What are the future plans for Nitinotes?
Nitinotes plans to launch the EndoZip System in European centers and is also preparing for a pivotal U.S. IDE trial to support FDA submission.
